A case of chemotherapy induced hemolytic anemia of choriocarcinoma combined with hereditary spherocytosis

作者：Lin, Yun; Wei, Xueli; Xue, Min; Deng, Xinliang; Sun, Xin^*

来源：International Journal of Clinical and Experimental Medicine, 2018, 11(3): 2736-2741.

• Choriocarcinoma
• hereditary spherocytosis
• hemolytic anemia

This study reported a case of hereditary spherocytosis patient presented hemolytic anemia during the chemotherapy of choriocarcinoma. A female patient aged 28 years old, gestation 5 times and pregnancy twice by cesarean section (G5P2), and admitted because of 5 months of postpartum vaginal bleeding. She was diagnosed as choriocarcinoma based on pathology and received uterine curettage. After surgery, she received etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine (EMA-CO) chemotherapy and resulted in severe anemia. Peripheral blood smear examination demonstrated a hereditary spherocytosis. EMA-CO chemotherapy was continued after blood transfusion, combined with.-globulin intravenous injection, and prednisone treatment. Blood beta-HCG did not decreased as expected, but elevated at the beginning of the third circle of chemotherapy, however, pelvic MRI presented unshrinking lesion. Thus, it was considered that EMA-CO resistance, and the patient underwent laparoscopy hysterectomy. Then she continued receiving EMA-CO chemotherapy postoperatively and the blood beta-HCG back to normal. Comprehensive monitoring the state of illness is crucial for chemotherapy, which may induce severe complications. Rational and individualized treatment can improve the clinical effect and avoid drug resistance.

• 出版日期2018
• 单位中南大学